Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Sidney Kimmel Comprehensive Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00255710 |
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclophosphamide, mycophenolate mofetil, and tacrolimus after transplant may stop this from happening.
PURPOSE: This phase I trial is studying cyclophosphamide and/or mycophenolate mofetil with or without tacrolimus to see which is the best regimen in treating patients who are undergoing a donor bone marrow or stem cell transplant for hematologic cancer.
Condition | Intervention | Phase |
---|---|---|
Chronic Myeloproliferative Disorders Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases |
Biological: filgrastim Drug: cyclophosphamide Drug: fludarabine phosphate Drug: mycophenolate mofetil Drug: tacrolimus Procedure: allogeneic bone marrow transplantation Procedure: peripheral blood stem cell transplantation Radiation: radiation therapy |
Phase I |
Study Type: | Interventional |
Study Design: | Supportive Care, Open Label |
Official Title: | Nonmyeloablative Bone Marrow Transplants in Hematologic Malignancies: Dose Finding Study for Post-Transplant Immunosuppression |
Estimated Enrollment: | 60 |
Study Start Date: | July 2002 |
OBJECTIVES:
OUTLINE:
Sequentially increasing levels of post-transplant immunosuppression: Cohorts of patients are enrolled into 1 of the following regimens:
Patients are followed for 60 days after transplantation.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following hematologic malignancies:
Myelofibrosis with ≥ 2 of the following high-risk features:
Mycosis fungoides, meeting 1 of the following criteria:
Stage IIB or III disease with evidence of histologic conversion to an aggressive lymphoma
Paroxysmal nocturnal hemoglobinuria
Diagnosis of 1 of the following hematologic malignancies, for which patient is not eligible for potentially curative allogeneic BMT due to end-organ dysfunction, age 65 to 75, or the amount of prior chemotherapy:
Acute myeloid or acute lymphoblastic leukemia
Relapsed aggressive non-Hodgkin's lymphoma
Hodgkin's lymphoma in second or further complete or partial remission
Myelodysplastic syndromes or myelodysplastic/myeloproliferative diseases
Any of the following subtypes:
Any subset with life-threatening cytopenias in all 3 cell lines, defined as platelet count
Meets both of the following criteria:
Stage III or IV chronic lymphocytic leukemia
Chronic myelogenous leukemia in first or second chronic phase
Stage III or IV indolent small lymphocytic or follicular lymphoma
PATIENT CHARACTERISTICS:
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY:
Chemotherapy
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Baltimore, Maryland, United States, 21231-2410 |
Study Chair: | Carol A. Huff, MD | Sidney Kimmel Comprehensive Cancer Center |
Study ID Numbers: | CDR0000449652, JHOC-J0169, WIRB-20020304 |
Study First Received: | November 18, 2005 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00255710 History of Changes |
Health Authority: | United States: Federal Government |
graft versus host disease adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) adult acute lymphoblastic leukemia in remission adult acute myeloid leukemia in remission chronic idiopathic myelofibrosis chronic myelomonocytic leukemia chronic phase chronic myelogenous leukemia myelodysplastic/myeloproliferative disease, unclassifiable previously treated myelodysplastic syndromes recurrent adult Burkitt lymphoma recurrent adult diffuse large cell lymphoma |
recurrent adult diffuse mixed cell lymphoma recurrent adult immunoblastic large cell lymphoma recurrent adult lymphoblastic lymphoma recurrent grade 3 follicular lymphoma recurrent mantle cell lymphoma stage II multiple myeloma stage III adult Hodgkin lymphoma stage III chronic lymphocytic leukemia stage III grade 1 follicular lymphoma stage III grade 2 follicular lymphoma stage III multiple myeloma stage III small lymphocytic lymphoma stage IV adult Hodgkin lymphoma stage IV chronic lymphocytic leukemia stage IV grade 1 follicular lymphoma |
Chronic Myelomonocytic Leukemia Lymphoma, Mantle-Cell Mycophenolic Acid Mantle Cell Lymphoma Tacrolimus Follicular Lymphoma Refractory Anemia Graft Versus Host Disease Mycoses Acute Myelocytic Leukemia Preleukemia Anemia, Refractory Hemorrhagic Disorders Acute Myeloid Leukemia, Adult Leukemia, Lymphocytic, Chronic, B-Cell |
Mycophenolate mofetil Neoplasm Metastasis Hodgkin Disease Myelodysplastic Myeloproliferative Disease Lymphoma, Large B-Cell, Diffuse Precursor Cell Lymphoblastic Leukemia-Lymphoma Immunoproliferative Disorders Hematologic Diseases Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Leukemia, Myelomonocytic, Chronic Blood Coagulation Disorders Myeloproliferative Disorders Leukemia, Myeloid Multiple Myeloma Fludarabine |
Antimetabolites Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Immunologic Factors Precancerous Conditions Antineoplastic Agents Blood Protein Disorders Physiological Effects of Drugs Mycophenolic Acid Paraproteinemias Tacrolimus Cyclophosphamide Antibiotics, Antineoplastic Hemostatic Disorders Leukemia |
Preleukemia Pathologic Processes Hemorrhagic Disorders Therapeutic Uses Syndrome Mycophenolate mofetil Cardiovascular Diseases Alkylating Agents Lymphoma Disease Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Hematologic Diseases Myelodysplastic Syndromes |